BioPharmSignal logoBioPharmSignal

Biotech News

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Innoviva (INVA)InnovivaCompany update

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive Company seeks pipeline expansion via industry partnerships LEXINGTON, Mass. --(BUSINESS WIRE)--Jun. 18, 2026-- Nortiva Bio, Inc.

Related news

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2025-10-20 12:00 EST

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

View all latest news

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-18 12:00 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

INVAInnoviva2026-06-01 15:00 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-05-06 20:05 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Stock data

Close
21.11 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States